SurModics Serene™ hydrophilic coatings address unmet need for
lubricious, low particulate medical device coatings
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Feb. 11, 2013--
SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface
modification for medical devices, today introduced SurModicsSerene™
lubricious coatings for endovascular medical devices. Serene
coatings are a breakthrough technology that delivers lubricity and
durability while significantly reducing particulates. They are optimized
for a wide range of catheter substrates and are used on FDA-cleared
coronary and peripheral devices. The new coating is being introduced at
the MD&M West meeting currently taking place in Anaheim, Calif.
“The Serene coating platform successfully addresses medical
device manufacturers’ interest in a high-performance lubricious coating
that also yields the lowest amount of particulates,” says Charlie Olson,
senior vice president and general manager of SurModics’ Medical Device
Particulate generation during endovascular procedures is an area of
interest for regulators. Several factors can contribute to particulate
generation: device materials and design, device coatings, clinical
technique, and the type of procedure. In recent years, manufacturers of
minimally invasive medical devices have received more characterization
requests from regulatory agencies seeking test results and
justifications for particulate levels associated with their coated
While medical device manufacturers cannot control all the variables that
may result in particulate generation, SurModicsSerene coatings
give them the option of a lower particulate coating platform that
optimizes both lubricity and durability.
“This next-generation coating is the culmination of several years of
development work,” says Gary Maharaj, president and chief executive
officer. “As a market leader in coatings, we will continue to create
innovative products that help advance our customers’ coronary,
peripheral, neuro, and structural heart devices.”
About SurModics, Inc.
mission is to exceed our customers’ expectations and enhance patients’
well-being by providing the world’s foremost, innovative surface
modification technologies and in vitro diagnostic chemical
components. SurModics partners with the world’s leading and emerging
medical device, diagnostic and life science companies to develop and
commercialize innovative products designed to improve patient diagnosis
and treatment. Core offerings include surface modification coating
technologies that impart lubricity, prohealing, and biocompatibility
characteristics, and components for in vitro diagnostic test kits
and microarrays. SurModics is headquartered in Eden Prairie, Minn. For
more information, visit www.surmodics.com.
The content of SurModics’ website is not part of this press release or
part of any filings that the Company makes with the SEC.
Source: SurModics, Inc.
Tim Arens, 952-500-7000
Finance and Interim Chief Financial Officer